"Bio Investment, Focusing Only on Contract Size is Certain Failure"... A New Drug Developer Talks About Real Opportunities [Kim Yu-shin's Deep Money Talk]
A new drug development expert warns against focusing solely on contract size in bio investment, emphasizing pipeline differentiation, cautioning against stock volatility from contract rumors, and highlighting opportunities in obesity and cancer treatment markets.
Get high-impact news instantly
Top stories with score 8/10+ delivered to your Telegram in real time. Free.
Join Telegram channel